BIRD-C is partnering its proprietary bacterial ghost technology with vaccine, pharma, cosmetics and biotech companies interested in using bacterial ghosts for the optimal immunogenic presentation of recombinant antigens, or entrapment and targeted delivery of active substances. Details on potential structures of such collaborations are available on request.
To get in touch with BIRD-C regarding joint product development and technology licensing please contact:
Alexander Matis, MSc, MBA
Business Development Manager